First Trust Nasdaq Pharmaceuticals ETF
FTXH
21 hedge funds and large institutions have $5.78M invested in First Trust Nasdaq Pharmaceuticals ETF in 2024 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 4 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
5% less funds holding
Funds holding: 22 → 21 (-1)
4.61% less ownership
Funds ownership: 43.5% → 38.88% (-4.6%)
23% less capital invested
Capital invested by funds: $7.55M → $5.78M (-$1.77M)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$390K |
| 2 |
LPL Financial
San Diego,
California
|
+$134K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$119K |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
+$66.9K |
| 5 |
AIP
Ameritas Investment Partners
Lincoln,
Nebraska
|
+$45.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$854K |
| 2 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$616K |
| 3 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$359K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$185K |
| 5 |
NS
NBC Securities
Birmingham,
Alabama
|
-$155K |
FTXH Hedge Fund Activity: Q4 2024 in Review
21 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q4 2024, worth a combined $5.78M — down 23% from $7.55M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of FTXH and 3 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 6 added.
The largest buyer was Cambridge Investment Research Advisors, opening a new position worth an estimated $390K. The largest seller was Goldman Sachs, cutting an estimated $854K.
- 21 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q4 2024, down from 22 in Q3 2024.
- Funds reported $5.78M of First Trust Nasdaq Pharmaceuticals ETF stock for Q4 2024, down 23% quarter-over-quarter.
- 3 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q4 2024 and 4 closed out, a net change of -1 holder.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q4 2024 was Cambridge Investment Research Advisors, an estimated $390K added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q4 2024 was Goldman Sachs, an estimated $854K sold.
Based on aggregated 13F filings for Q4 2024.